Wendell Miers, MD
Endocrinology, Diabetes & Metabolism · Lexington, KYNPI 1356403489
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $26,013 of the $38,241 with a category attached, or 68.0%. Novo Nordisk accounts for 65.0% of it on its own, with 44 other manufacturers making up the rest. Reporting peaked in 2019 at $21,154 and has fallen 96.2% since, to $808 in 2025.
Across 620 payments — averaging $61.68 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$25K
- Johnson & Johnson$4K
- Boehringer Ingelheim$745
- AstraZeneca$732
- Dexcom, Inc.$722
- Mannkind Corporation$693
- plus $6K from 39 others
Across 33 payments — averaging $4631.54 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Eli Lilly$114K
- AbbVie$33K
- Janssen Research & Development, LLC$6K
What the payments were for
- Speaking & faculty fees$26,01368%
- Travel & lodging$1,1513%
- Food & beverage$10,88728%
- Education$1410%
- Other$500%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Ozempic$11,449
- Tresiba$8,315
- INVOKANA$4,230
- RYBELSUS$1,989
- Kerendia$396
- MINIMED 780G$169
- Wegovy$110
- Yorvipath$106
- t-slim insulin pump$106
- Korlym$105
How this compares
$38,241 in reported general payments places this provider in the 85th percentile of 90 endocrinology, diabetes & metabolism providers in Kentucky.
See all endocrinology, diabetes & metabolism providers in Kentucky →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 710 | $1,115,366 |
| JardianceEmpagliflozin | 583 | $698,671 |
| TrulicityDulaglutide | 220 | $427,560 |
| MounjaroTirzepatide | 169 | $230,572 |
| FarxigaDapagliflozin Propanediol | 210 | $228,970 |
| Tresiba Flextouch U-200Insulin Degludec | 111 | $198,269 |
| Tresiba Flextouch U-100Insulin Degludec | 178 | $184,272 |
| JanuviaSitagliptin Phosphate | 150 | $175,573 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 123 | $123,308 |
| Omnipod 5 Dexg7g6 Pods (Gen 5)Insulin Pump Cart,auto,bt,g6/7 | 123 | $117,996 |
| RybelsusSemaglutide | 66 | $104,288 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 42 | $102,267 |
| InvokanaCanagliflozin | 54 | $89,612 |
| Novolog FlexpenInsulin Aspart | 114 | $45,294 |
| Soliqua 100-33Insulin Glargine/Lixisenatide | 34 | $41,206 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus, Fiasp, Novolog, Novolog Mix 70-30 | $24,870 | $1,277,703881 claims |
| Boehringer IngelheimJardiance, Tradjenta | $745 | $721,443599 claims |
| Lilly USA, LLCTrulicity, Mounjaro, Humalog | $309 | $673,500427 claims |
| AstraZenecaFarxiga | $732 | $228,970210 claims |
| MerckJanuvia, Janumet Xr | $195 | $201,050167 claims |
| Johnson & JohnsonInvokana | $4,428 | $89,61254 claims |
| Sanofi-aventis U.S. LLCSoliqua 100-33 | $434 | $41,20634 claims |
| AbbVieSynthroid | $296 | $36,184416 claims |
| BayerKerendia | $595 | $31,62718 claims |
| Amneal Pharmaceuticals LLCLevothyroxine Sodium | $56 | $14,038980 claims |
| Antares Pharma, Inc.Xyosted | $196 | $12,88017 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 90 endocrinology, diabetes & metabolism providers in Kentucky.
Other endocrinology, diabetes & metabolism in Lexington
- Lyle MyersLexington$60K
- Leera PatelLexington$34K
- Simon FisherLexington$26K
- Anna MarinoLexington$23K
- Gordon GuthrieLexington$14K
- Kenneth AinLexington$5K
- Megan MinchLexington$4K
- Walaa AyoubLexington$3K
- Kristina HumphriesLexington$3K
- Dennis KarounosLexington$3K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.